Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

New England Journal of Medicine

Volumn 357, Issue 21, 2007, Pages 2123-2132

  Dimopoulos, Meletios ^a   Spencer, Andrew ^b   Attal, Michael ^d   Prince, H Miles ^c   Harousseau, Jean Luc ^e   Dmoszynska, Anna ^f   San Miguel, Jesus ^g   Hellmann, Andrzej ^h   Facon, Thierry ⁱ   Foà, Robin ^j   Corso, Alessandro ^k   Masliak, Zvenyslava ^l   Olesnyckyj, Marta ^m   Yu, Zhinuan ^m   Patin, John ^m   Zeldis, Jerome B ^m   Knight, Robert D ^m  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ALFRED HOSPITAL   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d CHU PURPAN   (France)

^e HÔTEL DIEU   (France)

^f MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h MEDICAL UNIVERSITY OF GDANSK   (Poland)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^l Hematology Department of the Academy of Medical Sciences of Ukraine   (Ukraine)

^m CELGENE CORPORATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; PLACEBO; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BACTERIAL PNEUMONIA; BONE PAIN; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEATH; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEART ARREST; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INSOMNIA; LEUKOENCEPHALOPATHY; LUNG EMBOLISM; MALE; MEDIASTINUM DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; SUDDEN DEATH; THORAX DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION;

EID: 36349023319     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa070594     Document Type: Article

References (12)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-8.
2. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927-37.
3. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71. [Erratum, N Engl J Med 2000;342:364.]
4. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50.
5. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001;12:991-5.
6. Garcia-Sanz R, González-Porras JR, Hernández JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004;18:856-63.
7. Kumar S, Anderson KC. Drug insight: thalidomide as a treatment for multiple myeloma. Nat Clin Pract Oncol 2005;2:262-70.
8. Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004;117:508-15.
9. Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during costimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002;130:75-84.
10. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7.
11. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-64.
12. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.